Clearmind Medicine shares surge 38.92% after-hours as CMND-100 enters dosing phase with positive trial results.

Clearmind Medicine Inc. surged 38.92% in after-hours trading following the announcement that its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) advanced to the dosing phase, with the first participant enrolled and dosed at Hadassah-University Medical Center in Jerusalem. The trial, led by Prof. Joseph Caraco, is part of a multinational study evaluating CMND-100’s safety, tolerability, and efficacy. Positive top-line results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board to continue the trial were cited as key drivers. The company emphasized the milestone as a critical step in expanding its global trial footprint and advancing potential AUD treatments. The development underscores investor optimism about the drug candidate’s therapeutic potential and the company’s progress in addressing an underserved medical need.